(1996). Dijkman JH: Antibacterial activity of antileukoprotease. Infect Immun
(2002). Ding A: Conversion of proepithelin to epithelia’s: roles of SLPI and elastase in host defense and wound repair. Cell
(2010). Ding A: Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice.
(2000). Ding A: Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit Care Med
(2007). EF: Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol
(2008). Helicobacter pylori infection and short-term intake of low-dose aspirin have different effects on alpha-1 antitrypsin/alpha-1 peptidase inhibitor (alpha1-PI) levels in antral mucosa and peripheral blood.
(2006). Helicobacter pylori infection, but not low-dose aspirin, results in a local reduction of the secretory leukocyte protease inhibitor in gastroduodenal mucosa. Helicobacter
(2004). Helicobacter pylori-mediated gastritis induces local downregulation of secretory leukocyte protease inhibitor in the antrum. Infect Immun
(1998). HP: Granulins: the structure and function of an emerging family of growth factors.
(2003). Increased expression of the secretory leukocyte proteinase inhibitor in Wegener’s granulomatosis. Clin Exp Immunol
(1986). Inhibition of mast cell chymase by eglin c and antileukoprotease (HUSI-I). Indications for potential biological functions of these inhibitors. Biol.Chem.Hoppe Seyler
(2009). Innate immune responses of pulmonary epithelial cells to Burkholderia pseudomallei infection. PLoS One
(2008). IR: Progranulin: normal function and role in neurodegeneration.
(2008). KH: Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer.
(2007). Kraal G: Secretory leukoprotease inhibitor in mucosal lymph node dendritic cells regulates the threshold for mucosal tolerance.
(2006). Malfertheiner P: Helicobacter pylori-induced downregulation of the secretory leukocyte protease inhibitor (SLPI) in gastric epithelial cell lines and its functional relevance for H. pylorimediated diseases. Biol Chem
(2005). McElvaney NG: Secretory leucoprotease inhibitor binds to NFkappaB binding sites in monocytes and inhibits p65 binding. J Exp Med
(2006). Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature
(2003). Nibbering PH, van Dissel JT: Plasma secretory leukocyte protease inhibitor in febrile patients. Clin Microbiol Infect
(2009). Progranulin expression in advanced human atherosclerotic plaque. Atherosclerosis
(2008). Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin.
(2006). Sallenave JM: Human neutrophil elastase inhibitors in innate and adaptive immunity. Biochem Soc Trans
(2008). Sallenave JM: Human neutrophil elastase: mediator and therapeutic target in atherosclerosis.
(2010). Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity.
(2002). Simmen FA: Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes.
(2009). Taggart CC: Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.
(2011). Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response.